High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease.
Crohn’s disease
biologic therapy
clinical remission
clinical response
through levels
ulcerative colitis
ustekinumab
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2024
2024
Historique:
received:
15
02
2024
accepted:
26
06
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
Ustekinumab (UST) is an effective treatment option in Crohn's disease (CD) and ulcerative colitis (UC). However, it still remains unclear if therapeutic drug monitoring could be helpful to guide clinicians. The aim of our study was to analyze the relationship between UST through levels (UST We performed a unicentric retrospective study including patients with IBD under UST treatment with at least one level determination. The following variables were analyzed at the initiation of UST and at each UST We included 125 patients, 117 with CD. In P1, 62.4% of patients were on subcutaneous maintenance, and the median UST High serum levels of UST were associated with clinical remission during treatment for IBD under intensification treatment, with a cutoff point of 6.3 μg/mL.
Sections du résumé
Background
UNASSIGNED
Ustekinumab (UST) is an effective treatment option in Crohn's disease (CD) and ulcerative colitis (UC). However, it still remains unclear if therapeutic drug monitoring could be helpful to guide clinicians.
Objectives
UNASSIGNED
The aim of our study was to analyze the relationship between UST through levels (UST
Design
UNASSIGNED
We performed a unicentric retrospective study including patients with IBD under UST treatment with at least one level determination.
Methods
UNASSIGNED
The following variables were analyzed at the initiation of UST and at each UST
Results
UNASSIGNED
We included 125 patients, 117 with CD. In P1, 62.4% of patients were on subcutaneous maintenance, and the median UST
Conclusion
UNASSIGNED
High serum levels of UST were associated with clinical remission during treatment for IBD under intensification treatment, with a cutoff point of 6.3 μg/mL.
Identifiants
pubmed: 39257470
doi: 10.1177/17562848241271980
pii: 10.1177_17562848241271980
pmc: PMC11384525
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562848241271980Informations de copyright
© The Author(s), 2024.
Déclaration de conflit d'intérêts
All the authors declare that have received fees for papers, consultancies, research, or other collaborations from the following laboratories: MSD, Abbvie, Pfizer, Takeda, Janssen, Galapagos, Kern Pharma, Amgen, Sandoz.